FEops HEARTguide authorized by FDA for unprecedented LAAo planning capabilities
14 October 2021
FEops today announced that it received De Novo authorization from the U.S. Food and Drug Administration (FDA) for FEops HEARTguide™ pre-operative planning of left atrial appendage occlusion with the Boston Scientific WATCHMAN™ device*. FEops HEARTguide™ will enable physicians to virtually model clinical scenarios with different implant positions and sizes of the WATCHMAN™ device helping the heart team to select the optimal size and position for every individual patient. “The preoperative insight provided by FEops HEARTguide™ is powerful and can help me to opti-mize decision making for selecting optimal device size and position”, said Dr Jacqueline Saw, Van-couver General Hospital, Canada. “FEops HEARTguide™ is an intuitive platform I can use to discuss cases with the entire heart team to streamline my pre-op planning workflow.”
More info on FEops‘s website.